Central hemodynamics for risk reduction strategies: additive value over and above brachial blood pressure.

Abstract:

:Reduction strategies of blood pressure, as a modifiable cardiovascular risk, are currently based on office assessment of brachial artery blood pressure. However, antihypertensive treatment based on brachial BP values reduces cardiovascular risk but cannot completely reverse the hypertension-induced risk of morbidity events. As is well known, BP varies in different arterial systems and invasive and non-invasive studies have demonstrated that brachial BP does not necessarily reflect central aortic BP. Emerging evidences now suggest that central pressure may predict cardiovascular diseases better than brachial BP; moreover, it may differently respond to certain antihypertensive drugs. The potential effects beyond peripheral BP control may be due to specific protective properties of different antihypertensive drugs in affecting central aortic pressure and arterial stiffness. Although data on direct cardiovascular benefit impact of central blood pressure treatment in randomized clinical trials are still lacking, it is likely that the improvement of quality of care and the individualized assessment of the hypertension-associated cardiovascular risk are achievable with the use of central hemodynamics. Therefore, basing antihypertensive treatment guidance on central pressures rather than on peripheral blood pressure may be the key for future antihypertensive strategies.

journal_name

Curr Pharm Des

authors

Rinaldi ER,Yannoutsos A,Borghi C,Safar ME,Blacher J

doi

10.2174/1381612820666141023164530

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

730-6

issue

6

eissn

1381-6128

issn

1873-4286

pii

CPD-EPUB-63013

journal_volume

21

pub_type

杂志文章,评审
  • Prodrugs in genetic chemoradiotherapy.

    abstract::Improvements in the radiotherapeutic management of solid tumors through the concurrent use of gene therapy is a realistic possibility. Of the broad array of candidate genes that have been evaluated, those encoding prodrug-activating enzymes are particularly appealing since they directly complement ongoing clinical che...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612033454117

    authors: Patterson AV,Saunders MP,Greco O

    更新日期:2003-01-01 00:00:00

  • The importance of reendothelialization after arterial injury.

    abstract::Atherosclerosis is still the principal cause of morbidity and mortality in Western countries and although a significant progress has been made in the understanding of its pathophysiology, the determinants of atherosclerotic plaque instability are still poorly understood. The endothelium plays a pivotal role for the de...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161207780831239

    authors: Versari D,Lerman LO,Lerman A

    更新日期:2007-01-01 00:00:00

  • NAP (davunetide) provides functional and structural neuroprotection.

    abstract::NAP (davunetide) is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo. In human clinical trials, NAP has been shown to increase memory scores in patients suffering from amnestic mild cognitive impairment, a precursor to Alzheimer's disease and to enhance...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211795589373

    authors: Gozes I

    更新日期:2011-01-01 00:00:00

  • Activated immune system and inflammation in healthy ageing: relevance for tryptophan and neopterin metabolism.

    abstract::Immune activation not only accompanies inflammation in various disorders including infections, autoimmune syndromes and cancer, but it also represents a characteristic feature of ageing. Immune deviations which are most widely expressed in the elderly include increased neopterin production and tryptophan breakdown. Th...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666140317110217

    authors: Capuron L,Geisler S,Kurz K,Leblhuber F,Sperner-Unterweger B,Fuchs D

    更新日期:2014-01-01 00:00:00

  • Colchicum Genus in the Writings of Ancient Greek and Byzantine Physicians.

    abstract::The plants of the Colchicum family were known during the archaic period in Greece for their deleterious properties. Later on, they were used for the treatment of podagra. The treatment was introduced by the ancient Greek physicians and passed on to the Byzantine and Arabian physicians to endure until nowadays. The fir...

    journal_title:Current pharmaceutical design

    pub_type: 历史文章,杂志文章,评审

    doi:10.2174/1381612824666180115111546

    authors: Tsoucalas G,Papaioannou T,Panayiotakopoulos G,Saridaki Z,Vrachatis DA,Karamanou M

    更新日期:2018-01-01 00:00:00

  • Effects of metabolic approach in diabetic patients with coronary artery disease.

    abstract::The pivotal therapeutic role of myocardial metabolic modulation in ischemic heart disease (IHD) is increasingly recognized. Among the others, inhibitors of free fatty acids (FFA) oxidation have been consistently shown to play an important role in the therapeutic strategy of IHD patients. Additionally, abnormalities of...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209787582093

    authors: Fragasso G,Salerno A,Spoladore R,Cera M,Montanaro C,Margonato A

    更新日期:2009-01-01 00:00:00

  • Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).

    abstract:BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), termed coronavirus disease 2019 (COVID-19) by the World Health Organization, is a newly emerging zoonotic agent that emerged in China in December 2019. No specific treatment for COVID-19 is currently available. Usual palliative treatment includes ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666200707121636

    authors: Lovato ECW,Barboza LN,Wietzikoski S,de Souza ANV,Auth PA,Junior AG,Dos Reis Lívero FA

    更新日期:2020-07-07 00:00:00

  • CD164 as a Basophil Activation Marker.

    abstract::Introduction of flow cytometric technique to the research on basophil activation has led to significant achievements in allergy diagnosis in vitro. Most of the studies employing the flow cytometry used CD63 as a marker of basophil activation and only some of them used CD203c. Recently discovered basophil activation ma...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211798357890

    authors: Wolanczyk-Medrala A,Barg W,Medrala W

    更新日期:2011-11-01 00:00:00

  • Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease.

    abstract::Parkinson's disease (PD) is one of common neurodegenerative diseases, which shows motor symptoms including tremor, bradykinesia, rigidity and postural instability. It also involves non-motor symptoms such as cognitive impairment, mental manifestation, autonomic disorder and sensory disturbance. Although treatments to ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170710163731

    authors: Miyazaki I,Asanuma M

    更新日期:2017-01-01 00:00:00

  • Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning.

    abstract::An important goal of biomedical research is to translate basic research findings into practical clinical implementation. Despite the advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging. The failure rate for new drugs targeting important ce...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612826666200224112534

    authors: Morofuji Y,Nakagawa S

    更新日期:2020-01-01 00:00:00

  • Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases.

    abstract::Radiolabelled peptides and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation with clinical implications for several chronic inflammatory disorders for diagnosis, therapy decision making and follow up. In the last decades, a number of novel monoclonal antibodies and peptides h...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208785777414

    authors: Malviya G,Signore A,Laganà B,Dierckx RA

    更新日期:2008-01-01 00:00:00

  • Novel approach to cardiovascular diseases: a promising probability of (pro)renin receptor [(P)RR].

    abstract::Inhibition of the renin-angiotensin system (RAS) has been shown to have beneficial effects in cardiovascular disease prognosis and therapy.Discovery of (pro)renin receptor [(P)RR] revealed that (P)RR upon binding to both renin or prorenin in their proenzyme inactive form made them enzymatically active, thus aiding the...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/13816128113199990472

    authors: Ando T,Ichihara A

    更新日期:2014-01-01 00:00:00

  • Early life and oxidative stress in psychiatric disorders: what can we learn from animal models?

    abstract::Schizophrenia is a complex pathology characterized by the occurrence of a variety of symptoms classified as positive, negative and cognitive. Although the exact etiopathogenesis of this disorder has not been unraveled yet, many theories have been endorsed during the last years. Among these, the neurochemical theories ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150105122422

    authors: Mhillaj E,Morgese MG,Trabace L

    更新日期:2015-01-01 00:00:00

  • New perspectives in glioma immunotherapy.

    abstract::Glioblastoma (GBM) is a deadly tumor, which in spite of surgery and radio/chemotherapy frequently undergoes relapses related to the infiltration of the normal parenchyma and to resistance to cytotoxic and radiation therapy. Immunotherapy may represent a promising approach, which may complement existing therapies with ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211797249206

    authors: Daga A,Bottino C,Castriconi R,Gangemi R,Ferrini S

    更新日期:2011-01-01 00:00:00

  • Lone atrial fibrillation - a diagnosis of exclusion.

    abstract::Atrial fibrillation (AF) is the most common sustained rhythm disturbance, increasing prevalence with age, in particular in patients with cardiovascular disease. On the other hand, a subset of patients with AF being <60 years old and no evidence of underlying cardiovascular disease, and laboratory tests including thyro...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666140825142206

    authors: Tello-Montoliu A,Hernández-Romero D,Sanchez-Martínez M,Valdes M,Marín F

    更新日期:2015-01-01 00:00:00

  • Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach.

    abstract::The involvement of the central nervous system (CNS) is one of the major causes of morbidity and mortality in systemic lupus erythematosus (SLE) patients and the less understood aspect of the disease. Its recognition and treatment continue to represent a major diagnostic and therapeutic challenge. Due to the lack of co...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208799316401

    authors: Sanna G,Bertolaccini ML,Khamashta MA

    更新日期:2008-01-01 00:00:00

  • Growth differentiation factor 5 regulation in bone regeneration.

    abstract::Growth differentiation factor 5 (GDF5) is a member of the bone morphogenic protein (BMP) family and plays critical roles in organ development processes including bone, cartilage, ligament, and joint formation. GDF5 is expressed in the cartilage primordium in the early limb development, and in the interzone of joint fo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811319190003

    authors: Jin L,Li X

    更新日期:2013-01-01 00:00:00

  • Pathobiology of stent thrombosis after drug-eluting stent implantation.

    abstract::First generation drug-eluting stents (DES) have significantly improved the treatment options for patients with symptomatic coronary artery disease by decreasing rates of acute vessel closure and restenosis after percutaneous coronary revascularization procedures. However, early enthusiasm was temperd by reports of lat...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210794454879

    authors: Vorpahl M,Yazdani SK,Nakano M,Ladich E,Kolodgie FD,Finn AV,Virmani R

    更新日期:2010-01-01 00:00:00

  • Targeted drugs and nanomedicine: present and future.

    abstract::Packaging small-molecule drugs into nanoparticles improves their bio-availability, bio-compatibility and safety profiles. Multifunctional particles carrying large drug payloads for targeted transport, immune evasion and favourable drug release kinetics at the target site, require a certain minimum size usually 30-300 ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209787002870

    authors: Debbage P

    更新日期:2009-01-01 00:00:00

  • Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors.

    abstract::Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations of target-specific agents could counteract this response providing a useful strategy in ca...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Porcelli L,Quatrale AE,Mantuano P,Silvestris N,Rolland JF,Biancolillo L,Paradiso A,Azzariti A

    更新日期:2013-01-01 00:00:00

  • Pharmacophore identification and quantitative bioactivity prediction using the electron-conformational method.

    abstract::A review of the Electron-Conformational (EC) method of pharmacophore (Pha) identification and quantitative bioactivity prediction in drug design and toxicology is presented, which includes the latest advances and improvements of the method as a whole and details of its realization with illustration of results. In the ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612033454586

    authors: Bersuker IB

    更新日期:2003-01-01 00:00:00

  • Novel targets for antiinflammatory and antiarthritic agents.

    abstract::Inflammation is a complex pathological condition associated with exaggerated human immune system involving various activated immune cells and bio-molecules. Treatment of inflammatory diseases particularly chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease etc. has been a big challen...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206777698945

    authors: Kulkarni RG,Achaiah G,Sastry GN

    更新日期:2006-01-01 00:00:00

  • Hypericin--the facts about a controversial agent.

    abstract::Hypericin is a naturally occurring substance found in the common St. John's Wort (Hypericum species) and can also be synthesized from the anthraquinone derivative emodin. As the main component of Hypericum perforatum, it has traditionally been used throughout the history of folk medicine. In the last three decades, hy...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612053382287

    authors: Kubin A,Wierrani F,Burner U,Alth G,Grünberger W

    更新日期:2005-01-01 00:00:00

  • Cyclooxygenase and atherosclerosis: a smoking area.

    abstract::Chronic smoking is associated with functional and structural vascular changes underlying inflammatory processes responsible for plaque formation and rupture. Cyclooxygenase (COX) is the key enzyme linking smoking action to inflammatory damages: it is responsible for the conversion of arachidonic acid to prostanoids, a...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210792062902

    authors: Pistoia F,Cipollone F,Ferri C,Sarà M,Sudano I,Desideri GB

    更新日期:2010-01-01 00:00:00

  • The role of bevacizumab in advanced epithelial ovarian cancer.

    abstract:BACKGROUND:There is a strong rationale for usage of anti-angiogenic agents in epithelial ovarian cancer. Bevacizumab is the most widely investigated anti-VEGF agent and has shown promising results in recent clinical trials. OBJECTIVE:To review the rationale and usage of bevacizumab in advanced epithelial ovarian cance...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161212802002689

    authors: Kroep JR,Nortier JW

    更新日期:2012-01-01 00:00:00

  • Clinical Approach for the Treatment of Obesity-associated Diseases.

    abstract:: ...

    journal_title:Current pharmaceutical design

    pub_type: 社论

    doi:10.2174/138161282518190822153931

    authors: Isenovic ER

    更新日期:2019-01-01 00:00:00

  • Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature.

    abstract:BACKGROUND:Cardiovascular disease has been the leading cause of death in both sexes in developed countries for decades. In general, men and women share the same cardiovascular risk factors. However, in recent trials including both men and women sexspecific analyses have raised awareness of sex differences in cardiovasc...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666160309115318

    authors: Pedersen LR,Frestad D,Michelsen MM,Mygind ND,Rasmusen H,Suhrs HE,Prescott E

    更新日期:2016-01-01 00:00:00

  • Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy.

    abstract::Histone lysine methylation can be modified by various writers and erasers. Different from other epigenetic modifications, mono-, di, and tri- methylation distinctly modulate chromatin structure and thereby contribute to the regulation of DNA-based nuclear processes such as transcription, replication and repair on thei...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666160715125417

    authors: Zheng YC,Ma JL,Liu Y,Liu HM

    更新日期:2016-01-01 00:00:00

  • Regulatory T cells and tolerogenic dendritic cells as critical immune modulators in atherogenesis.

    abstract::Innate and adaptive immunity has been shown to be critically involved in the pathogenesis of atherosclerosis. In particular, immune suppression mediated by regulatory T cells (Tregs) or tolerogenic dendritic cells (DCs) serves as a vital mechanism for regulating pathogenic chronic inflammation in atherogensis, suggest...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666141013142518

    authors: Sasaki N,Yamashita T,Kasahara K,Takeda M,Hirata K

    更新日期:2015-01-01 00:00:00

  • Role of DAP12 in innate and adaptive immune responses.

    abstract::DAP12 is a novel immunoreceptor tyrosine-based activation motifs (ITAM)-bearing transmembrane adapter molecule. This molecule, together with its partner receptor complex molecules including the killer cell activating receptors (KARs), myeloid DAP12 associating lectin-1 (MDL-1), triggering receptor expressed on myeloid...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612033392503

    authors: Aoki N,Kimura S,Xing Z

    更新日期:2003-01-01 00:00:00